two-kidney, one-clip hypertensive rats Effect of pravastatin on left ventricular mass in the

You might find this additional information useful... This article cites 44 articles, 21 of which you can access free at: http://ajpheart.physiology.org/cgi/content/full/291/6/H2705#BIBL Updated information and services including high-resolution figures, can be found at: http://ajpheart.physiology.org/cgi/content/full/291/6/H2705 Additional material and information about AJP - Heart and Circulatory Physiology can be found at: http://www.the-aps.org/publications/ajpheart This information is current as of November 8, 2006 . € ISSN: 0363-6135, ESSN: 1522-1539. Visit our website at http://www.the-aps.org/.

[1]  T. Chou,et al.  Association of Pravastatin and Left Ventricular Mass in Hypercholesterolemic Patients: Role of 8-Iso-Prostaglandin F2&agr; Formation , 2002, Journal of cardiovascular pharmacology.

[2]  K. Node,et al.  Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. , 2001, The Journal of clinical investigation.

[3]  T. Chou,et al.  Differential Role of KATP Channels Activated by Conjugated Estrogens in the Regulation of Myocardial and Coronary Protective Effects , 2003, Circulation.

[4]  C. Kahn,et al.  Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. , 2002, The Journal of clinical investigation.

[5]  A. Wilde,et al.  Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. , 1997, Cardiovascular research.

[6]  J. Kawabe,et al.  Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. , 1999, European journal of pharmacology.

[7]  N. Chang,et al.  Adjunctive 17beta-estradiol administration reduces infarct size by altered expression of canine myocardial connexin43 protein. , 2004, Cardiovascular research.

[8]  T. Lee,et al.  Effect of pravastatin on myocardial protection during coronary angioplasty and the role of adenosine. , 2001, The American journal of cardiology.

[9]  J. Rouleau,et al.  Markedly different effects on ventricular remodeling result in a decrease in inducibility of ventricular arrhythmias. , 1994, Journal of the American College of Cardiology.

[10]  H. Lane,et al.  p70s6k function is essential for G1 progression , 1993, Nature.

[11]  S. Bishop,et al.  Regional myocyte size in two-kidney, one clip renal hypertension. , 1988, Journal of molecular and cellular cardiology.

[12]  N. Beier,et al.  NHE-1-dependent intracellular sodium overload in hypertrophic hereditary cardiomyopathy: prevention by NHE-1 inhibitor. , 2005, Journal of molecular and cellular cardiology.

[13]  N. Chang,et al.  Effect of pravastatin on left ventricular mass by activation of myocardial K ATP channels in hypercholesterolemic rabbits. , 2004, Atherosclerosis.

[14]  M. Horie,et al.  Endothelin-1 inhibition of cardiac ATP-sensitive K+ channels via pertussis-toxin-sensitive G-proteins. , 1997, Cardiovascular research.

[15]  M. Maioli,et al.  Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients , 2000, European journal of clinical investigation.

[16]  B. McDermott,et al.  Temporal characteristics of cardiomyocyte hypertrophy in the spontaneously hypertensive rat. , 2004, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[17]  A. Bauch,et al.  Endothelin system-dependent cardiac remodeling in renovascular hypertension. , 1999, Hypertension.

[18]  Guo-shu Liu,et al.  A New ATP-Sensitive Potassium Channel Opener Protects the Kidney from Hypertensive Damage in Spontaneously Hypertensive Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.

[19]  Rui Wang,et al.  Altered Vascular Reactivity and KATP Channel Currents in Vascular Smooth Muscle Cells from Deoxycorticosterone Acetate (DOCA)-Salt Hypertensive Rats , 2004, Journal of cardiovascular pharmacology.

[20]  E. Ritz,et al.  Myocyte loss in early left ventricular hypertrophy of experimental renovascular hypertension , 2003, Virchows Archiv.

[21]  Ying Xia,et al.  Inhibition of phenylephrine induced hypertrophy in rat neonatal cardiomyocytes by the mitochondrial KATP channel opener diazoxide. , 2004, Journal of molecular and cellular cardiology.

[22]  M. Pahor,et al.  Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. , 1999, Hypertension.

[23]  Effects of angiotensin-converting enzyme inhibition and calcium channel blockade on cardiac apoptosis in rats with 2K1C (two-kidney/one-clip) renovascular hypertension. , 2003 .

[24]  T. Chou,et al.  Effects of pravastatin on cardiomyocyte hypertrophy and ventricular vulnerability in normolipidemic rats after myocardial infarction. , 2003, Journal of molecular and cellular cardiology.

[25]  Xiao-Ping Yang,et al.  Effect of ACE Inhibitors and Angiotensin II Type 1 Receptor Antagonists on Endothelial NO Synthase Knockout Mice With Heart Failure , 2002, Hypertension.

[26]  L. D. de Windt,et al.  Enhanced Activity of the Myocardial Na+/H+ Exchanger NHE-1 Contributes to Cardiac Remodeling in Atrial Natriuretic Peptide Receptor–Deficient Mice , 2005, Circulation.

[27]  K. Hasegawa,et al.  Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 1990, Biochimica et biophysica acta.

[28]  N. Standen,et al.  Angiotensin II inhibits rat arterial KATP channels by inhibiting steady‐state protein kinase A activity and activating protein kinase Ce , 2001, The Journal of physiology.

[29]  M. Phillips,et al.  Antisense Inhibition of Brain Renin-Angiotensin System Decreased Blood Pressure in Chronic 2-Kidney, 1 Clip Hypertensive Rats , 2001, Hypertension.

[30]  S. Su,et al.  Differential effects of sarcolemmal and mitochondrial K(ATP) channels activated by 17 beta-estradiol on reperfusion arrhythmias and infarct sizes in canine hearts. , 2002, The Journal of pharmacology and experimental therapeutics.

[31]  B. Buckley,et al.  Statins do more than just lower cholesterol , 1996, The Lancet.

[32]  G. Faury,et al.  Highly Protective Effects Of Chronic Oral Administration Of Nicorandil On The Heart Of Ageing Rats , 2002, Clinical and experimental pharmacology & physiology.

[33]  S. Chae,et al.  Glibenclamide suppresses stretch-activated ANP secretion: involvements of K+ATP channels and L-type Ca2+ channel modulation , 1997, Pflügers Archiv.

[34]  M. Hori,et al.  Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signal-regulated kinase. , 2002, Journal of the American College of Cardiology.

[35]  M. Hori,et al.  Long-Acting Ca2+ Blockers Prevent Myocardial Remodeling Induced by Chronic NO Inhibition in Rats , 2003, Hypertension.

[36]  D. Levy,et al.  Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. , 1998, Journal of the American College of Cardiology.

[37]  K. Leineweber,et al.  Ventricular Hypertrophy Plus Neurohumoral Activation Is Necessary to Alter the Cardiac &bgr;-Adrenoceptor System in Experimental Heart Failure , 2002, Circulation research.

[38]  S. Aslam,et al.  Roles of Oxidative Stress and AT1 Receptors in Renal Hemodynamics and Oxygenation in the Postclipped 2K,1C Kidney , 2003, Hypertension.

[39]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[40]  R. Marchase,et al.  Hyperglycemia inhibits capacitative calcium entry and hypertrophy in neonatal cardiomyocytes. , 2002, Diabetes.

[41]  John C. Lee,et al.  Extracellular Signal-regulated Kinase Plays an Essential Role in Hypertrophic Agonists, Endothelin-1 and Phenylephrine-induced Cardiomyocyte Hypertrophy* , 2000, The Journal of Biological Chemistry.

[42]  S. Su,et al.  Pharmacologic preconditioning of estrogen by activation of the myocardial adenosine triphosphate-sensitive potassium channel in patients undergoing coronary angioplasty. , 2002, Journal of the American College of Cardiology.